Vietnam Chronic Cough Therapeutics Market Analysis

Vietnam Chronic Cough Therapeutics Market Executive Summary

Vietnam's Chronic Cough Therapeutics Market was valued at $32 Mn in 2022 and is estimated to reach $60 Mn in 2030, exhibiting a CAGR of 8.33% during the forecast period.

A chronic cough is characterized by its persistence for more than eight weeks, setting it apart from short-term coughs associated with temporary conditions. In contrast to transient coughs typically linked to infections, a chronic cough may indicate a prolonged underlying health issue. Conditions such as asthma, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), postnasal drip, and certain medications are common culprits behind chronic cough. It is crucial to identify and address the underlying cause through a comprehensive medical evaluation for effective management. Chronic cough can significantly impact the quality of life, often necessitating a holistic, multidisciplinary approach that involves healthcare professionals like pulmonologists, gastroenterologists, or ear, nose, and throat (ENT) specialists.

A major health concern in Vietnam is chronic cough, which is influenced by several factors. The epidemiology of chronic cough in Asian countries including Vietnam is impacted by various factors, such as exposure to pollutants, potentially serious infections, and unique population-based characteristics. Notably, in Vietnam, persistent cough prevalence differs between urban and rural areas, with the former having a higher prevalence (18.1%) than the latter (12.0%). The prevalence of conditions such as tuberculosis and paragonimiasis among individuals experiencing chronic cough is noteworthy in the Vietnamese context. Moreover, air pollution is identified as a significant factor in developing persistent respiratory problems, highlighting the significant influence of environmental factors on respiratory health in the area. The various contributing factors and distinct epidemiological patterns of chronic cough in Vietnam emphasize how crucial it is to have a thorough understanding to develop public health policies and interventions that are effective.

Levoquin (levofloxacin) inhalation solution received FDA approval, representing a major success for Novartis. This approval is specifically related to its use in the treatment of Pseudomonas aeruginosa lung infections in patients with cystic fibrosis. Such infections are known to be a common contributor to chronic cough in affected individuals. With this regulatory approval, Levoquin's therapeutic potential as a targeted treatment for respiratory issues related to cystic fibrosis is highlighted, providing patients with this illness with a promising alternative for improving their quality of life.

Market Dynamics

Market Growth Drivers

Rising prevalence of chronic cough: The incidence of chronic cough is on the rise in Vietnam, attributed to factors such as escalating air pollution, smoking, and an aging demographic. Various underlying conditions, including asthma, chronic obstructive pulmonary disease (COPD), and gastroesophageal reflux disease (GERD), can contribute to the onset of chronic cough and expansion of the chronic cough therapeutics market.

Growing awareness of chronic cough: Increasing awareness of chronic cough in Vietnam has resulted in a rising number of individuals actively pursuing diagnosis and treatment. This trend is fuelled by various factors, including government-led public health initiatives, extensive media coverage, and the ready accessibility of health information online.

Changing Lifestyles and Environmental Factors: Changing lifestyles, urbanization, and increased exposure to environmental pollutants are driving the rise in respiratory disorders, leading to an increased need for chronic cough therapeutics.

Market Restraints

Side Effects and Safety Concerns: Potential side effects or safety concerns associated with certain chronic cough therapeutics may raise apprehensions among both healthcare providers and patients. This could lead to a more cautious adoption of these treatments, impacting market growth.

Reliance on Symptomatic Treatment: The predominant use of symptomatic treatment approaches for chronic cough, rather than addressing the underlying causes, may limit the effectiveness of available therapeutics. This reliance on managing symptoms rather than curing the root cause can be a constraint in achieving long-term success.

Cultural Perceptions and Traditional Remedies: People might turn to homeopathic or traditional remedies influenced by cultural attitudes and preferences, impacting their perception of persistent coughs. Encouraging the acceptance of modern treatment alternatives among both healthcare professionals and patients could present a challenge for the industry.

Healthcare Policies and Regulatory Landscape

In Vietnam, the Ministry of Health (MOH) and its subordinate entity, the Drug Administration of Vietnam (DAV), play a central role in managing healthcare policies and regulatory oversight related to therapeutic drugs. Acting as the overarching authority, the MOH develops and enforces policies that govern the approval, importation, manufacturing, and distribution of pharmaceuticals, including those used in treatments. The DAV, functioning under the MOH, assumes a crucial role in drug-related affairs by overseeing the registration, licensing, quality control, and inspection of pharmaceutical products. The National Pharmaceutical Control Bureau (NPCB) is responsible for conducting testing and ensuring quality assurance. The overall framework incorporates regulations for clinical trials, adherence to Good Manufacturing Practice (GMP), and compliance with import and export regulations. It is imperative to consider health insurance policies and coverage for treatment drugs, reflecting Vietnam's ongoing commitment to maintaining a well-regulated healthcare system that prioritizes the safety, efficacy, and accessibility of pharmaceutical treatments.

Competitive Landscape

Key Players

• AstraZeneca
• Boehringer Ingelheim
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Abbott Laboratories
• Merck
• Teva Pharmaceuticals
• Mekophar
• Traphaco
• Sao Thai Duong